source
- Medtronic veteran Bill Shields crosses over to become CEO at valve disease startupAfter 15 years with Medtronic’s structural heart franchise, Bill Shields is leaving the medtech giant to become the chief executive of startup Versa Vascular.Fierce Biotech · 17h ago↗ source
- Braveheart Bio raises $382.5M in IPO to fund phase 3 trial of cardiac drugBraveheart Bio, a San Francisco biotech, completed an IPO that raised $382.5 million, exceeding its original target. The company increased the share count to 21.2 million and set the price at $18…